CSL shares have come under pressure recently. Is this one of those rare moments when a top-tier blue chip becomes a genuine ...

Blood plasma is big business — especially along the U.S.–Mexico border. Every day, thousands of Mexican citizens cross ...

CSL ( ($AU:CSL) ) just unveiled an update. CSL Limited announced the cessation of 32,733 securities due to the lapse of conditional rights, as the ...

CSL ( ($AU:CSL) ) has issued an announcement. CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a recent ...

Another ASX stock that could be a great option for a $2,000 investment is WiseTech Global. It has also experienced a rare pullback in 2025, despite continuing to strengthen its position as one of the ...

CSL Behring, the CSL’s plasma business, generated $11.16bn in revenue in 2024. Credit: ArDanMe via Shutterstock.com. CSL will outlay $1.5bn over the next five years in the US to grow its footprint of ...

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

Imagine having an on-call research assistant that can analyze mountains of work and web data to give you insightful expertise in minutes, whether you’re preparing for a big meeting, brainstorming new ...

CSL Limited announced the cessation of 50,194 securities due to the lapse of conditional rights, as the conditions were not met or became unachievable. This development may impact the company’s ...

Carlisle Companies remains a Buy, with a target price lowered to $358 (10% upside) due to more conservative financial assumptions. CSL's Q3 results were mixed, with stable revenue supported by ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...